There are currently 80 clinical trials in Riverside, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Kaiser Permanente-Riverside, GSK Investigational Site, Artemis Institute for Clinical Research and Novartis Investigative Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988
Recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/06/2025
Locations: Kaiser Permanente-Riverside Medical Center, Riverside, California
Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Stage I Breast Cancer
Register for Updates
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
Recruiting
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/01/2025
Locations: SCPMG/Kaiser Permanente Riverside Medical Center, Riverside, California
Conditions: Wet Age Related Macular Degeneration, wAMD
Register for Updates
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
05/01/2025
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Register for Updates
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
05/01/2025
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Breast Cancer
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
NCT06307665
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/30/2025
Locations: Research Site, Riverside, California
Conditions: Asthma
Register for Updates
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Los Angeles cancer Network_Riverside, Riverside, California
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Register for Updates
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
NCT06848075
Recruiting
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/22/2025
Locations: Artemis Institute for Clinical Research - Riverside, Riverside, California
Conditions: Acute Migraine
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: CiTrials, Riverside, California
Conditions: Major Depressive Disorder
Register for Updates
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026
Recruiting
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Medvin Clinical Research - Riverside, Riverside, California
Conditions: Psoriatic Arthritis, Overweight or Obesity
Register for Updates